Recent BioUtah News & Events

CAMBRIDGE, Mass., April 10, 2021 — Sumitomo Dainippon Pharma Oncology, Inc., a clinicalstage company focused on research and development for novel cancer therapeutics, today presented new findings on a range of investigational agents from the company’s pipeline at the American Association for Cancer Research (AACR) Virtual Annual Meeting I, taking place April 10-15, 2021. The […]

On Wednesday, President Biden unveiled the first installment of his two-part Build Back Better plan – a sweeping $2.25 trillion infrastructure proposal billed as the American Jobs Plan.  In addition to fixing highways, bridges and roads, which accounts for approximately 5% of the plan ( $620 billion), the measure calls for a myriad of administration […]

Congress is once again turning its attention to drug pricing, including the proposed use of foreign reference pricing models. Foreign reference pricing was part of the Lower Drug Costs Now Act passed by House Democrats in 2019 (also known as H.R. 3) and has resurfaced in legislation, the Prescription Drug Price Relief Act, recently introduced […]

BioUtah has submitted a comment letter to CMS in response to concerns raised by the Biden administration around the Medicare Coverage of Innovative Technology (MCIT) rule finalized under President Trump on January 14. The MCIT program was set to take effect on March 15, but on March 12, in the form of an interim final […]

Fluidx’s regulatory and clinical affairs director will take the reins of the Regulation, Compliance and Quality Committee, utilizing his expertise to help guide the regulatory and quality activities of BioUtah, the state’s premier life sciences trade association. Christopher Phillips, director of regulatory affairs and clinical affairs at Fluidx Medical Technology, has been appointed chair of […]

Lehi-based Sumitomo Dainippon Pharma Oncology (SDP Oncology) recently presented new findings on a range of investigational agents from the company’s pipeline at the American Association for Cancer Research (AACR) Virtual Annual Meeting I. The data presented at the meeting include preclinical and Phase 1 clinical data evaluating the potential anti-cancer activity of the PKM2 activator […]

PhotoPharmics has announced its intent to leverage its FDA breakthrough device designation, potential streamlined Medicare coverage under CMS’ pending Medicare Coverage of Innovative Technology (MCIT) rule and global delivery channels to deliver its treatments for Parkinson’s and neurodegenerative diseases to individuals regardless of their location or income. Innovation not only brings improved treatments to address […]

Xenter has announced its formal launch in Salt Lake City. Founded in 2020 by seasoned life sciences entrepreneur Richard J. Linder, Xenter is innovating new wireless technologies and techniques for the treatment of heart and vascular disease. The company’s next-generation devices will integrate functions that formerly required multiple costly devices. “We are bringing the world’s […]

Recursion Pharmaceuticals, Inc. today announced the pricing of its initial public offering of its Class A common stock at a price to the public of $18.00 per share. Recursion is offering 24,242,424 shares of its Class A common stock. The gross proceeds from the offering are expected to be $436.4 million. The shares are expected to […]

IONIQ Sciences was awarded another patent for “an apparatus for providing information that is useful in the diagnosis of a malignant lung lesion.” IONIQ’s newest Notice of Allowance by the State Intellectual Property Office of the People’s Republic of China (SIPO) covers critical advancements and refinements to our proprietary algorithm, which calculates the likelihood a […]

IONIQ Sciences, Inc. recently announced that Raphael E. Pollock, MD, PhD, FACS has joined its Medical Advisory Committee. Dr. Pollock is an award-winning surgical oncologist, extensively published physician- scientist, Professor Emeritus in the Department of Surgical Oncology at MD Anderson Cancer Center and currently the Director of The Ohio State University Comprehensive Cancer Center (OSUCCC). […]

Policymakers in Washington are considering plans to replace the current market-based system for pricing prescription medicines with a system based on foreign reference pricing. If enacted, this policy will import to the US price controls that foreign countries use to deny patients access to the newest cures and treatments. It could also impede innovation and […]